HSBC Call 100 BAYN 18.06.2025/ DE000HG3Y2R5 /
6/24/2024 9:00:43 PM | Chg.0.000 | Bid6/24/2024 | Ask6/24/2024 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.001EUR | 0.00% | 0.001 Bid Size: 120,000 |
0.017 Ask Size: 20,000 |
BAYER AG NA O.N. | 100.00 - | 6/18/2025 | Call |
GlobeNewswire
2:00 PM
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at The...
GlobeNewswire
2:00 PM
Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results ...
GlobeNewswire
5/30
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
5/30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
5/2
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
4/18
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
4/16
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
4/11
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
3/25
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
3/6
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
3/4
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
2/13
Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...